Skip to main content
Caplight Logo









Nervonik

Nervonik

Private
Los Angeles, CaliforniaHealthcare & Life Scienceshttps://nervonik.com/

Last Round

Series B

Apr 27, 2026

Est. Valuation

$121M

Total Funding Raised

$74.3M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Nervonik is a therapeutic devices company that develops miniaturized, power-efficient neuromodulation implants and peripheral nerve stimulation (PNS) systems for chronic neuropathic pain.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Keywords

peripheral nerve stimulationPNSneuromodulationchronic pain managementimplantable medical deviceclosed-loop stimulationneuropathic painbioelectronic medicineneural sensingECAPminimally invasive surgerypain techmedtechsmart implantnon-opioid pain relief

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nervonik Comparables

Compare Nervonik with similar companies based on industry and business-model similarity.

Nervonik comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neuros Medical
87%
SPR Therapeutics
84%
Curonix
84%

Nervonik Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 27, 2026
Series AMar 4, 2025

Key People

Founding team and executive leadership

Aydin Babakhani

Founder and CEO

Founding Team

Nervonik Investors

Notable investors and investment history

Nervonik investors
InvestorRounds
Amzak HealthSeries B
U.S. Venture PartnersSeries B, Series A
Foothill VenturesSeries A, Series B
Seraph GroupConvertible Debt, Seed
Joyance PartnersConvertible Debt, Seed
ShangBay CapitalConvertible Debt, Series B, Seed
Lumira VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased to 3, 3x the trailing average.

  • Apr 27, 2026

    $53M round led by Amzak Health.

Recent news

Latest coverage and updates

  • hiresJul 13, 2026

    Nervonik, Inc hires Rob.

  • is_developingJul 13, 2026

    Nervonik, Inc is developing peripheral nerve stimulation platform.

  • is_developingJul 13, 2026

    Nervonik, Inc is developing minimally invasive peripheral nerve stimulation system designed to treat chronic pain on Jul 13th '26.

  • hiresJul 13, 2026

    Nervonik, Inc hired Patrick Martin as vice president of clinical affairs on Jul 13th '26.

  • hiresJul 13, 2026

    Nervonik, Inc hired Rob DiTota as Chief Commercial Officer on Jul 13th '26.

Nervonik Filings

Explore SEC and related filing metadata, where available.

Nervonik filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersLos Angeles, California
Employee Range13
Year Founded2020
Last FundingApr 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?